NCT03714555 - Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 17, 2019

Primary Completion Date

July 22, 2020

Study Completion Date

July 29, 2020

Conditions

Metastatic Pancreatic Cancer

Interventions

DIAGNOSTIC_TEST

Safety Laboratories

Complete blood cell count (CBC) w Differential, comprehensive metabolic panel (CMP), Prothrombin time/international normalized ratio (PT/INR) Activated Partial Thromboplastin Time (aPTT), Urinalysis

OTHER

AE Assessment

Assessment of Adverse Events (AE)

OTHER

Physical Exam

Physical Exam, Weight, Vital Signs, Eastern Cooperative Oncology Group (ECOG) Performance Status

OTHER

Concomitant Medication Review

Prior and Concomitant Medication Review

DIAGNOSTIC_TEST

Tumor Imaging

Tumor CT or MRI

DRUG

nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate

nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing

DRUG

FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate

FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate dispensing

DRUG

Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate

Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing

Trial Locations (1)

85251

HonorHealth Research Institute, Scottsdale